Article
The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells.
Oncogene - 19 Apr 2012
Durán-Prado M, Gahete M D, Hergueta-Redondo M, Martínez-Fuentes A J, Córdoba-Chacón J, Palacios J, Gracia-Navarro F, Moreno-Bueno G, Malagón M M, Luque R M, Castaño J P
Abstract excerpt
Somatostatin receptors (sst1-5) are present in different types of tumors, where they inhibit key cellular processes such as proliferation and invasion. Although ssts are densely expressed in breast cancer, especially sst2, their role and therapeutic potential remain uncertain. Recently, we identified a new truncated sst5 variant, sst5TMD4, which is related to the abnormal response of certain pituitary tumors to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.